Verona Pharma plc (VRNA)
NASDAQ: VRNA · Real-Time Price · USD
105.20
+0.01 (0.01%)
At close: Aug 13, 2025, 4:00 PM
105.11
-0.09 (-0.09%)
After-hours: Aug 13, 2025, 7:41 PM EDT
Verona Pharma Stock Forecast
Stock Price Forecast
According to 10 professional analysts, the 12-month price target for Verona Pharma stock ranges from a low of $57 to a high of $170. The average analyst price target of $114.1 forecasts a 8.46% increase in the stock price over the next year.
Price Target: $114.10 (+8.46%)
Analyst Consensus: Buy
* Price targets were last updated on Jul 14, 2025.
Analyst Ratings
The average analyst rating for Verona Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 3 | 3 |
| Buy | 3 | 1 | 1 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 5 | 5 | 8 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $90 → $107 | Strong Buy → Hold | Downgrades | $90 → $107 | +1.71% | Jul 14, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $138 → $107 | Buy → Hold | Downgrades | $138 → $107 | +1.71% | Jul 10, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 10, 2025 |
| Jefferies | Jefferies | Strong Buy → Hold Downgrades $140 → $107 | Strong Buy → Hold | Downgrades | $140 → $107 | +1.71% | Jul 9, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy → Hold Downgrades $107 | Strong Buy → Hold | Downgrades | $107 | +1.71% | Jul 9, 2025 |
Financial Forecast
Revenue This Year
420.86M
from 42.28M
Increased by 895.44%
Revenue Next Year
748.13M
from 420.86M
Increased by 77.76%
EPS This Year
0.21
from -2.16
EPS Next Year
1.54
from 0.21
Increased by 635.37%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 491.4M | 943.3M | 1.3B | ||
| Avg | 420.9M | 748.1M | 1.1B | ||
| Low | 361.7M | 545.6M | 747.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1,062.3% | 124.1% | 69.0% | ||
| Avg | 895.4% | 77.8% | 44.5% | ||
| Low | 755.5% | 29.6% | -0.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.70 | 3.98 | 4.76 |
| Avg | 0.21 | 1.54 | 3.07 |
| Low | -0.11 | 0.37 | 0.46 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 1,803.2% | 209.3% |
| Avg | - | 635.4% | 99.3% |
| Low | - | 78.1% | -70.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.